New hope for kids with tough leukemia: trial tests Triple-Drug attack
NCT ID NCT06448013
Summary
This study is testing a new combination of three drugs—ziftomenib, venetoclax, and gemtuzumab—for children and young adults whose acute myeloid leukemia has come back or hasn't responded to other treatments. The main goal is to find the safest and most effective dose of this combination. Researchers will also check if the treatment helps control the leukemia and monitor how patients respond over time.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.